Phio Pharmaceuticals Corp.
PHIO- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001533040
In the last 90 days, Phio Pharmaceuticals Corp. insiders filed 5 open-market purchases and 0 sales; 24 institutions reported holding it in 13F filings for Q2 2026, worth $662.6K in total; no superinvestor holds it.
Q1 2024 vs. Q4 2023
How the institutions holding Phio Pharmaceuticals Corp. changed between Q4 2023 and Q1 2024.
All holders in Q1 2024All holders in Q4 2023
| Measure | Q4 2023 | Q1 2024 | Change |
|---|---|---|---|
| Holders | 14 | 10 | −4 |
| Shares | 506.9K | 150.5K | −356.4K (−70.3%) |
| Value | $388.8K | $106.1K | −$282.6K (−72.7%) |
New holders (1)
Institutions that held Phio Pharmaceuticals Corp. at the end of Q1 2024 but not at the end of Q4 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| UBS Group AG | 1,358 | $923 | 0.00% |
Sold out (5)
Institutions that held Phio Pharmaceuticals Corp. at the end of Q4 2023 and filed for Q1 2024 without it.
| Institution | Shares, Q4 2023 | Value, Q4 2023 |
|---|---|---|
| Sabby Management, LLC | 172,693 | $131.2K |
| Anson Funds Management LP | 157,425 | $119.6K |
| Citadel Advisors LLC | 31,843 | $24.2K |
| Renaissance Technologies LLC | 21,056 | $16.0K |
| Morgan Stanley | 125 | $95 |